Skip to main content

Table 2 Demographic characteristics, cognitive test scores, APO E allele distribution, brain volumetric measures, and cerebrospinal fluid biomarkers at baseline and follow-up for the final analysis set (115 MCI subjects) and the two groups MCI-stable and MCI-AD

From: Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

 

All (n = 115)

MCI-stable (n = 87)

MCI-AD (n = 28)

Standard mean difference*

P value**

Age (years)

65.7 ± 9.03

(36–89)

66.5 ± 8.95

(51–80)

65.4 ± 9.37

(36–89)

0.12

ns

Education (years schooling)

9.50 ± 1.91

(7–13)

9.75 ± 1.95

(7–13)

8.75 ± 1.58

(7–13)

–0.52

<0.05

Gender (female = 1, male = 2)

Male = 67;

female = 48

Male = 52;

female = 35

Male = 15;

female = 13

0.13

ns

Bayer-ADL scale (score: 1–10)

2.47 ± 1.48

(1–4)

2.41 ± 1.52

(1–4)

2.67 ± 1.34

(1–4)

0.18

ns

MADRS (score: 0–60)

7.41 ± 5.75

(0–13)

7.67 ± 5.96

(0–13)

6.62 ± 5.08

(0–11)

–0.18

ns

MMSE

27.0 ± 2.12

(20–30)

27.5 ± 1.87

(22–30)

25.8 ± 2.34

(20–29)

–0.81

<0.001

CDR-sb

1.80 ± 1.06

(0.5–4.5)

1.59 ± 1.00

(0.5–4.5)

2.45 ± 0.98

(0.5–4)

0.81

<0.001

CERAD-DR-WL

4.82 ± 2.33

(0–10)

5.25 ± 2.23

(0–10)

3.46 ± 2.15

(0–8)

–0.77

0.001

Amnestic deficit: CERAD-DR-WL below cut-off (<7 correct responses), n (% present)

88 (77%)

62 (71%)

26 (93%)

  

ApoE4 alleles (homo- or heterozygotes), n/sample size (% present)

41/103 (40%)

32/78 (41%)

9/25 (36%)

 

ns

Hippocampal volume (mm3)

4450 ± 672

(2509–5996)

4585 ± 649

(3036–5996)

4031 ± 570

(2509–5235)

–0.82

<0.0001

Total tau in CSF (pg/ml)

411 ± 252

(112–1169)

351 ± 205

(112–1158)

596 ± 294

(156–1169)

0.97

<0.0001

Total tau in CSF below cut-off (>300 pg/ml), n (% abnormal)

65 (57%)

41 (47%)

24 (86%)

  

Phosphorylated tau in CSF (pg/ml)

61.3 ± 30.5

(19.7–157)

55.6 ± 26.3

(19.7–130)

78.8 ± 36.1

(27.3–157)

0.76

<0.01

Phosphorylated tau in CSF below cut-off (>60 pg/ml), n (% abnormal)

44 (38%)

27 (31%)

17 (61%)

  

Aβ42 in CSF (pg/ml)

749 ± 300

(245–1792)

794 ± 309

(276–1792)

611 ± 223

(245–1134)

–0.61

<0.001

Aβ42 in CSF below cut-off (<600 pg/ml), n (% abnormal)

39 (34%)

22 (25%)

17 (61%)

  

Aβ40 in CSF (pg/ml)

9654 ± 2731

(2604–16320)

9601 ± 2561

(4175–16320)

9817 ± 3251

(2604–15210)

0.08

ns

Aβ40 in CSF below cut-off, n (% abnormal)

n/a

n/a

n/a

  

Follow-up time (months)

25.5 ± 9.8

(12–36)

26.1 ± 8.0

(12–36)

25.2 ± 8.9

(12–36)

 

ns

  1. Values are given as means ± SD (range) unless otherwise stated
  2. *Standardized (mean values in MCI-AD patients – mean values in MCI-stable patients)/standard deviation in the group of all patients
  3. **P values refer to differences between MCI-stable and MCI-AD
  4. Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, AD Alzheimer’s disease, B-ADL Bayer activities of daily living, CDR-sb Clinical Dementia Rating–sum-of-boxes, CERAD-DR-WL Consortium to Establish a Registry of Dementia–delayed recall word list, CSF cerebrospinal fluid, MADRS Montgomery-Asberg Depression Rating Scale, MCI cognitive impairment, MMSE Mini-Mental State Examination, n/a not available, ns not significant
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193